MTOR and autoimmune polyendocrinopathy: Additionally, supplementary agents that could be contemplated include hydroxychloroquine, which has exhibited both anti-inflammatory and anti-thrombotic properties in cases of SLE; statins, renowned for their anti-inflammatory effects in small cohorts of patients with APS and their ability to reduce the incidence of venous thromboembolism in larger population studies; and sirolimus, an mTOR inhibitor that has demonstrated efficacy in mitigating renal vasculopathy following APS-associated nephropathy.